Terms: = Endocrine gland cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Clinical Outcome
42 results:
1. Monitoring of circulating tumour DNA in advanced pancreatic ductal adenocarcinoma predicts clinical outcome and reveals disease progression earlier than radiological imaging.
Edland KH; Tjensvoll K; Oltedal S; Dalen I; Lapin M; Garresori H; Glenjen N; Gilje B; Nordgård O
Mol Oncol; 2023 Sep; 17(9):1857-1870. PubMed ID: 37341038
[TBL] [Abstract] [Full Text] [Related]
2. kras mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.
McHenry A; Rottmann DA; Buza N; Hui P
Virchows Arch; 2023 Jul; 483(1):71-79. PubMed ID: 37219599
[TBL] [Abstract] [Full Text] [Related]
3. Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.
Thomson JP; Hollis RL; van Baal J; Ilenkovan N; Churchman M; van de Vijver K; Dijk F; Meynert AM; Bartos C; Rye T; Croy I; Diana P; van Gent M; Creedon H; Nirsimloo R; Nussey F; Lok C; Herrington CS; Gourley C
Gynecol Oncol; 2023 Jul; 174():157-166. PubMed ID: 37207500
[TBL] [Abstract] [Full Text] [Related]
4. Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer.
Reissig TM; Tzianopoulos I; Liffers ST; Rosery VK; Guyot M; Ting S; Wiesweg M; Kasper S; Meister P; Herold T; Schmidt HH; Schumacher B; Albers D; Markus P; Treckmann J; Schuler M; Schildhaus HU; Siveke JT
ESMO Open; 2023 Jun; 8(3):101539. PubMed ID: 37148593
[TBL] [Abstract] [Full Text] [Related]
5. TIMEAS, a promising method for the stratification of testicular germ cell tumor patients with distinct immune microenvironment, clinical outcome and sensitivity to frontline therapies.
Meng J; Gao J; Li X; Gao R; Lu X; Zhou J; Yan F; Wang H; Liu Y; Hao Z; Zhang X; Liang C
Cell Oncol (Dordr); 2023 Jun; 46(3):745-759. PubMed ID: 36823338
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals kras G12D and Mutant TP53 Combination as an Independent Predictor of clinical outcome.
Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
[TBL] [Abstract] [Full Text] [Related]
7. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome.
Hollis RL; Thomson JP; Stanley B; Churchman M; Meynert AM; Rye T; Bartos C; Iida Y; Croy I; Mackean M; Nussey F; Okamoto A; Semple CA; Gourley C; Herrington CS
Nat Commun; 2020 Oct; 11(1):4995. PubMed ID: 33020491
[TBL] [Abstract] [Full Text] [Related]
8. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma.
Tu B; Yao J; Ferri-Borgogno S; Zhao J; Chen S; Wang Q; Yan L; Zhou X; Zhu C; Bang S; Chang Q; Bristow CA; Kang Y; Zheng H; Wang H; Fleming JB; Kim M; Heffernan TP; Draetta GF; Pan D; Maitra A; Yao W; Gupta S; Ying H
JCI Insight; 2019 Nov; 4(21):. PubMed ID: 31557131
[TBL] [Abstract] [Full Text] [Related]
9. Phellodendrine chloride suppresses proliferation of kras mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis.
Thu PM; Zheng ZG; Zhou YP; Wang YY; Zhang X; Jing D; Cheng HM; Li J; Li P; Xu X
Eur J Pharmacol; 2019 May; 850():23-34. PubMed ID: 30716311
[TBL] [Abstract] [Full Text] [Related]
10. Early Loss of Forkhead Transcription Factor, O Subgroup, Member 1 Protein in the Development of Pancreatic Ductal Adenocarcinoma.
Al-Zoughbi W; Schauer S; Pichler M; Hoefler G
Pathobiology; 2018; 85(5-6):342-347. PubMed ID: 30227407
[TBL] [Abstract] [Full Text] [Related]
11. Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy.
Necchi A; Bratslavsky G; Corona RJ; Chung JH; Millis SZ; Elvin JA; Vergilio JA; Suh J; Ramkissoon S; Severson E; Daniel S; Killian JK; Ali SM; Schrock AB; Reddy P; Miller VA; Welsh A; Gay LM; Ross JS
Eur Urol Focus; 2020 Jan; 6(1):122-130. PubMed ID: 30025711
[TBL] [Abstract] [Full Text] [Related]
12. Evolutionary routes and kras dosage define pancreatic cancer phenotypes.
Mueller S; Engleitner T; Maresch R; Zukowska M; Lange S; Kaltenbacher T; Konukiewitz B; Öllinger R; Zwiebel M; Strong A; Yen HY; Banerjee R; Louzada S; Fu B; Seidler B; Götzfried J; Schuck K; Hassan Z; Arbeiter A; Schönhuber N; Klein S; Veltkamp C; Friedrich M; Rad L; Barenboim M; Ziegenhain C; Hess J; Dovey OM; Eser S; Parekh S; Constantino-Casas F; de la Rosa J; Sierra MI; Fraga M; Mayerle J; Klöppel G; Cadiñanos J; Liu P; Vassiliou G; Weichert W; Steiger K; Enard W; Schmid RM; Yang F; Unger K; Schneider G; Varela I; Bradley A; Saur D; Rad R
Nature; 2018 Feb; 554(7690):62-68. PubMed ID: 29364867
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic Implications of Multiplex Detection of
Kim MK; Woo SM; Park B; Yoon KA; Kim YH; Joo J; Lee WJ; Han SS; Park SJ; Kong SY
Clin Chem; 2018 Apr; 64(4):726-734. PubMed ID: 29352043
[TBL] [Abstract] [Full Text] [Related]
14. Overexpression of the Long Noncoding RNA HomeoboxA Transcript at the Distal Tip Predicts Poor Prognosis in a kras-Independent Manner in Periampullary Region Tumors.
Balcin O; Ak Aksoy S; Tunca B; Kaya E; Egeli U; Tezcan G; Ugras N; Cecener G; Isik O; Dundar HZ; Yerci O
Pancreas; 2018 Feb; 47(2):213-220. PubMed ID: 29329159
[TBL] [Abstract] [Full Text] [Related]
15. Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
[TBL] [Abstract] [Full Text] [Related]
16. kras mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.
Zuo T; Wong S; Buza N; Hui P
Mod Pathol; 2018 Feb; 31(2):350-357. PubMed ID: 29027536
[TBL] [Abstract] [Full Text] [Related]
17. Expression of the scaffold connector enhancer of kinase suppressor of Ras 1 (CNKSR1) is correlated with clinical outcome in pancreatic cancer.
Quadri HS; Aiken TJ; Allgaeuer M; Moravec R; Altekruse S; Hussain SP; Miettinen MM; Hewitt SM; Rudloff U
BMC Cancer; 2017 Jul; 17(1):495. PubMed ID: 28732488
[TBL] [Abstract] [Full Text] [Related]
18. Treatment of Pancreatic cancer by Aptamer Conjugated C/EBPα-saRNA.
Yoon S; Rossi JJ
Adv Exp Med Biol; 2017; 983():173-188. PubMed ID: 28639199
[TBL] [Abstract] [Full Text] [Related]
19. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes.
Schlitter AM; Segler A; Steiger K; Michalski CW; Jäger C; Konukiewitz B; Pfarr N; Endris V; Bettstetter M; Kong B; Regel I; Kleeff J; Klöppel G; Esposito I
Sci Rep; 2017 Feb; 7():41064. PubMed ID: 28145465
[TBL] [Abstract] [Full Text] [Related]
20. Prolonged survival in pancreatic cancer patients with increased regucalcin gene expression: Overexpression of regucalcin suppresses the proliferation in human pancreatic cancer MIA PaCa-2 cells in vitro.
Yamaguchi M; Osuka S; Weitzmann MN; El-Rayes BF; Shoji M; Murata T
Int J Oncol; 2016 May; 48(5):1955-64. PubMed ID: 26935290
[TBL] [Abstract] [Full Text] [Related]
[Next]
